gms | German Medical Science

Introduction: The interim analysis of the COMPACT study assessed patient usage behaviour and feelings of self-administered injection with a self-injection device (SD) using the validated Self-Injection Assessment Questionnaire1 (SIAQ) in patients with rheumatoid arthritis (RA) receiving the approved etanercept biosimilar SDZ-ETN (GP2015).

Methods: COMPACT study is being conducted in Europe and Canada in SDZ-ETN treated patients (≥18 years of age) with RA, ankylosing spondylitis, or psoriatic arthritis. SIAQ assessment was done at week 12 and data was summarised using descriptive statistics. The SIAQ has PRE (before first self-injection) and POST (after dosing) modules. The POST module includes 21 items grouped into 6 hypothetical domains: “feelings about injection”, “self-image”, “self-confidence”, “injection-site reactions”, “ease of use of self-injection device (SD)”, and “satisfaction with self-injection”. The results for the “satisfaction with self-injection” domain (containing 8 questions, each rated on a 5-point scale) from German RA patients are reported here.

Results: In Germany, 92 RA patients who used the SD responded to the questionnaire. Based on the responses, majority of patients were “satisfied” or “very satisfied” with use of SD (Table); 81.5% of patients responded that the device was “convenient” or “very convenient” to use and 84.7% chose to continue self-injection after the study. The majority of patients reported to be “not at all” or only “a little” bothered by pain at the injection site (69.5%), or redness at the injection site (90.2%) (Table 1 [Tab. 1]).

Conclusion: The interim analysis results, although descriptive, show a clear trend for the ease of use and good satisfaction with SDZ-ETN SD in patients with RA.

Disclosures: None declared